AlphAIAlphAI — Financial news for AI agents
insurancejournal.comSEP 163 min read$ABT

Abbott to Pay $385 Million to End Claims Over Infant Formula

Abbott Laboratories will pay $385 million to settle U.S. claims over alleged poor manufacturing practices at its infant formula facilities, including a plant in Michigan linked to a 2022 recall and nationwide shortage. The settlement resolves allegations of unsanitary conditions and contamination risks, though Abbott denies liability. The company will pay $348.7 million to the U.S. and $36.3 million to states, with whistleblowers receiving $69 million. This follows a separate $670 million settle

Original reporting
insurancejournal.com
Published Sep 16, 2026, 6:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 16, 2026, 6:29 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott to Pay $385 Million to End Claims Over Infant Formula — source image
Source · insurancejournal.com
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The settlement resolves longstanding litigation but underscores operational risks; investors may reassess Abbott's compliance controls.

02

Market read

A major legal settlement for a large U.S. health‑care firm, likely to affect its short‑term stock price and sector risk perception.

03

What to watch

Potential insurance recoveries, the impact of prior $670 million settlement, and any upcoming FDA inspections.

Relevance 8/10Novelty 8/10Timing: announcement day

Background

Abbott faced FDA citations in 2022 for unsanitary conditions at its Sturgis, Michigan infant‑formula plant, leading to a nationwide shortage.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott Laboratories announced a $385 million settlement to resolve U.S. False Claims Act allegations over infant‑formula manufacturing.

Expected impact

Potential short‑term downside of 2‑4% as investors price in the payout and possible future scrutiny.

Evidence & confidence

Large, newly disclosed legal settlement; market typically reacts negatively to unexpected cash penalties of this magnitude.

Market effects

Sector

Highlights regulatory and quality‑control risks for the nutrition and consumer‑health sector.

Regional

May affect sentiment toward U.S. healthcare manufacturers, especially those with infant‑formula lines.

Global

Sets a precedent for enforcement actions on food‑safety compliance worldwide.

Counterpoint

What could challenge this read

If the settlement is fully accounted for and Abbott's broader pipeline remains strong, the stock could rebound quickly.

Key entities

  • company
    Abbott Laboratories

    U.S. healthcare and nutrition company settling the lawsuit.

  • government
    U.S. Department of Justice

    Brought the False Claims Act allegations.

Read at source← All news

Also covered by

6 outlets

Related articles

SEP 15
$ABTMedAI 8/10

Oregon gets $977k from settlement over baby formula safety allegations

Abbott Laboratories will pay $384M to settle allegations of unsafe manufacturing conditions for baby formula and nutritional products. Oregon receives $977,558. The settlement covers violations from 2018-2022, with Abbott paying $348.7M to the federal government and $35.5M to 39 states for Medicaid claims. The affected products were sold through government assistance programs like WIC and Medicaid.

ktvz.com2 min
SEP 15
$ABTLow

Baby formula maker to pay nearly $385 million to settle case involving contamination

Abbott Laboratories will pay $385 million to settle U.S. and state allegations regarding manufacturing practices at its Michigan and Arizona facilities from 2018 to 2022, according to the DOJ. The settlement resolves claims of false submissions to government programs due to alleged contamination risks and inadequate testing. Abbott will pay $348.7 million to the federal government and $36.3 million to states. Three whistleblowers will receive $69 million.

local12.com1 min
SEP 15
$ABTLow

Abbott Faces $384 Million Cost as Infant Formula Legal Risks Persist

Abbott Laboratories (ABT) will pay $384 million to resolve U.S. Justice Department allegations regarding infant formula production. The settlement addresses civil claims and closes the criminal investigation, but litigation risks persist. Abbott's Q2 2026 sales were $12.6 billion, with adjusted EPS guidance of $5.45-$5.60. The company aims to refocus on broader growth despite ongoing reputational and legal concerns.

insidermonkey.com3 min